tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SNBL’s Satsuma Pharma Achieves FDA Milestone

SNBL’s Satsuma Pharma Achieves FDA Milestone

Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has received FDA acceptance for the resubmission of its NDA for STS101, a novel treatment for acute migraine. This milestone aligns with SNBL’s financial forecasts for the fiscal year ending March 2025, as the U.S. market for such treatments exceeds $1 billion.

For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1